TY - JOUR
T1 - The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer
AU - Zhao, Lujun
AU - Sheldon, Kerby
AU - Chen, Ming
AU - Yin, Moli S.
AU - Hayman, James A.
AU - Kalemkerian, Gregory P.
AU - Arenberg, Doug
AU - Lyons, Susan E.
AU - Curtis, Jeffrey L.
AU - Davis, Mary
AU - Cease, Kemp B.
AU - Brenner, Dean
AU - Anscher, Mitchell S.
AU - Lawrence, Theodore S.
AU - Kong, Feng Ming
N1 - Funding Information:
The authors are grateful to Dawn Gustitus, Kristin Brierley, and Richard Otta for carefully handling of the blood samples to make this work possible. This work was supported in part by American Society of Clinical Oncology Young Investigator Award, a seed Award from Radiology Society and North American and Pardee Foundation.
PY - 2008/2
Y1 - 2008/2
N2 - Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.
AB - Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.
KW - Lung cancer
KW - Radiation therapy
KW - Radiation-induced lung toxicity
KW - Transforming growth factor β1
UR - http://www.scopus.com/inward/record.url?scp=38649099697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38649099697&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2007.08.010
DO - 10.1016/j.lungcan.2007.08.010
M3 - Article
C2 - 17905467
AN - SCOPUS:38649099697
SN - 0169-5002
VL - 59
SP - 232
EP - 239
JO - Lung Cancer
JF - Lung Cancer
IS - 2
ER -